Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | BCL2 | P10415 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | RPA1 | P27694 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915848 | 0.90 | CA9 (0.63) | CA9CHRNA7FAAHBCL2MDM2 | |
| SCHEMBL5522388 | 0.90 | CA9 (0.49) | CA9CHRNA7FAAHRPA1PTGS2 | |
| SCHEMBL2921056 | 0.89 | CA9 (0.54) | CA9CHRNA7FAAHBCL2MDM2 | |
| SCHEMBL2917961 | 0.89 | CA9 (0.54) | CA9CHRNA7FAAHBCL2MDM2 | |
| SCHEMBL14504359 | 0.89 | CA9 (0.54) | CA9CHRNA7FAAHBCL2MDM2 | |
| SCHEMBL2916480 | 0.88 | CHRNA7 (0.64) | CA9CHRNA7FAAHMALT1RPA1 | |
| SCHEMBL2913443 | 0.88 | CHRNA7 (0.64) | CA9CHRNA7FAAHBCL2MDM2 | |
| SCHEMBL2918939 | 0.88 | CA9 (0.63) | CA9CHRNA7FAAHBCL2MDM2 | |
| SCHEMBL5524665 | 0.87 | RPA1 (0.54) | BCL2MDM2MCL1MEN1KMT2A | |
| SCHEMBL5265828 | 0.86 | CA9 (0.51) | CA9CHRNA7FAAHBCL2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | CA9 3499/4885CHRNA7 4667/4885FAAH 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.